Exwannabe, thanks for clarifying.
So tax loss carry forward is limited to valuation/earnings by PPHM or the PPHM intellectual property that translates to earnings for the Pharma down the road, with annual limitations.
If PPHM has accumulated losses of $600 million that reflect the cost of developing their tech, building out Avid, running trials and such, it appears that there is a basis for TLCF to offset earnings posted by the acquiring Pharma over time plus for reducing the recognized book price for the acquisition.
I agree, figuring out such analysis on a message board is not a good match, at least until an acquiring interest's situation is defined.
Best wishes and IMO.
KT
Market Data 
Markets 
AI
